Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tempo-4 Tavapadon Open-Label Trial in Parkinson’s Disease
2024-512123-37-00Phase 3Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of tavapadon in Parkinson's disease (PD), sponsored by Cerevel Therapeutics. Started Jun 2024; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-512123-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512123-37-00.